Log in
Enquire now
GrayBug

GrayBug

GrayBug is a pharmaceutical company developing therapies for ocular diseases founded in 2011.

OverviewStructured DataIssuesContributors

Contents

graybug.com
graybug.vision
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Engineering
Engineering
Biomedical engineering
Biomedical engineering
Consumer biotechnology
Consumer biotechnology
Technology
Technology
Healthcare
Healthcare
Biology
Biology
Biotechnology
Biotechnology
...
Location
Baltimore
Baltimore
0
Redwood City, California
Redwood City, California
B2X
B2B
B2B
0
CEO
‌
Fred Guerard
0
AngelList URL
angel.co/graybug
Pitchbook URL
pitchbook.com/profiles.../59097-16
Legal Name
Graybug Vision, Inc.
Number of Employees (Ranges)
1 – 100
Email Address
bd@graybug.vision0
info@graybug.vision0
media@graybug.vision0
ir@graybug.vision0
Phone Number
+14438532377
Full Address
6411 Beckley Street Suite North 200 (N200) Baltimore, MD 212240
CIK Number
1,534,1330
Place of Incorporation
Delaware
Delaware
0
Investors
OrbiMed
OrbiMed
CBC Group
CBC Group
Hatteras Venture Partners
Hatteras Venture Partners
Deerfield Management
Deerfield Management
Blackstone Life Sciences
Blackstone Life Sciences
DUNS Number
9685103750
IRS Number
452,120,0790
Founded Date
2011
0
Total Funding Amount (USD)
81,500,000
Latest Funding Round Date
August 2019
Stock Symbol
GRAY0
Exchange
Nasdaq
Nasdaq
0
Board of Directors
Christina M. Ackermann
Christina M. Ackermann
0
‌
Eric Bjerkholt
0
‌
Fred Guerard
0
‌
Julie Eastland
0
‌
Dirk Sauer
0
‌
Christy Shaffer
0
Latest Funding Type
Series C
Series C
CAGE Code
6JAP00
Patents Assigned (Count)
1
Wellfound ID
graybug
Country
United States
United States
0

Other attributes

Company Operating Status
Active
Previous Name
GRAYBUG LLC0
GRAYBUG, Inc.0
SIC Code
2,8340
Ticker Symbol
GRAY

It is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Its novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like GrayBug

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.